Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Feb 28;17(8):1082-7.
doi: 10.3748/wjg.v17.i8.1082.

Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer

Xiao-Dong Li  1 , Hua Shen, Jing-Ting Jiang, Han-Ze Zhang, Xiao Zheng, Yong-Qian Shu, Chang-Ping Wu
Affiliations
Randomized Controlled Trial

Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer

Xiao-Dong Li et al. World J Gastroenterol. .

Abstract

Aim: To compare the efficacy and safety of paclitaxel combined with fluorouracil plus cisplatin (PCF), and oxaliplatin combined with fluorouracil plus leucovorin (FOLFOX-4) regimens for advanced gastric cancer (AGC).

Methods: Ninety-four patients with AGC were randomly assigned to receive paclitaxel (50 mg/m(2) iv) on days 1, 8 and 15, cisplatin (20 mg/m(2) iv) and fluorouracil (750 mg/m(2) iv) on days 1-5, or oxaliplatin (85 mg/m(2) iv) and leucovorin (200 mg/m(2) iv) on day 1, followed by bolus fluorouracil (400 mg/m(2) iv) and fluorouracil (600 mg/m(2) iv) on days 1 and 2. The primary end point was the 1-year survival time.

Results: The overall response rate (ORR) of the patients was 48.0% and 45.5% to PCF and FOLFOX-4, respectively. The disease control rate (DCR) of PCF and FOLFOX-4 was 82.0% and 81.8%, respectively. The median survival times (MSTs) of the patients were 10.8 and 9.9 mo, respectively, after treatment with PCF and FOLFOX-4. The 1-year survival rate of the patients was 36.0% and 34.1%, respectively, after treatment with PCF and FOLFOX-4. No significant difference was observed in ORR, DCR, MST or 1-year survival rate between the two groups. The most common adverse events were anemia, nausea and vomiting, and grade 3/4 alopecia in PCF treatment group, and anemia, grade 1/2 neurotoxic effect and grade 3/4 neutropenia in FOLFOX-4 treatment group.

Conclusion: Patients with AGC have a similar response rate to PCF and FOLFOX-4 regimens with a similar survival rate. The PCF and FOLFOX-4 regimens are efficacious and tolerable as a promising therapy for AGC.

Keywords: Advanced gastric cancer; Oxaliplatin; Paclitaxel.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival curves for patients in PCF and FOLFOX-4 groups. PCF: Paclitaxel combined with fluorouracil plus cisplatin; FOLFOX-4: Oxaliplatin combined with fluorouracil plus leucovorin.
See this image and copyright information in PMC

References

    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. - PubMed
    1. Shen X, Zhang J, Yan Y, Yang Y, Fu G, Pu Y. Analysis and estimates of the attributable risk for environmental and genetic risk factors in gastric cancer in a Chinese population. J Toxicol Environ Health A. 2009;72:759–766. - PubMed
    1. Wilke H, Preusser P, Fink U, Achterrath W, Mayer HJ, Stahl M, Lenaz L, Meyer J, Siewert JR, Gerlings H. New developments in the treatment of gastric carcinoma. Cancer Treat Res. 1991;55:363–373. - PubMed
    1. Rivera F, Vega-Villegas ME, López-Brea MF. Chemotherapy of advanced gastric cancer. Cancer Treat Rev. 2007;33:315–324. - PubMed
    1. Macdonald JS. Treatment of localized gastric cancer. Semin Oncol. 2004;31:566–573. - PubMed

Publication types